Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,733
Total Claims
$2.3M
Drug Cost
414
Beneficiaries
$5,521
Cost/Patient
Risk Score Breakdown 10/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+417%
Cost per patient vs peers
$5,521 vs $1,068 avg
+154%
Brand preference vs peers
22.9% vs 9.0% avg
Brand vs Generic
Brand: 1,978 claims · $2.1M
Generic: 6,678 claims · $223K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 267 | $270K |
| Semaglutide | 178 | $233K |
| Empagliflozin | 197 | $210K |
| Icosapent Ethyl | 282 | $192K |
| Linaclotide | 114 | $126K |
| Finerenone | 87 | $91K |
| Lipase/Protease/Amylase | 39 | $78K |
| Semaglutide | 54 | $76K |
| Rivaroxaban | 73 | $74K |
| Denosumab | 42 | $70K |
| Budesonide/Glycopyr/Formoterol | 52 | $50K |
| Sacubitril/Valsartan | 42 | $48K |
| Empagliflozin/Metformin Hcl | 43 | $46K |
| Lipase/Protease/Amylase | 19 | $32K |
| Insulin Degludec/Liraglutide | 12 | $24K |
Prescribing Profile
Patient Profile
72
Avg Age
47%
Female
0.89
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data